The stock of Beam Therapeutics Inc (NASDAQ: BEAM) has decreased by -2.13 when compared to last closing price of 19.71.Despite this, the company has seen a loss of -2.92% in its stock price over the last five trading days. globenewswire.com reported 2025-04-05 that New Data Demonstrate Proportion of Corrected M-AAT Reached a Mean of 91% of Total AAT in Circulation at Day 28 Following BEAM-302 Treatment in 60 mg Cohort (n=3)
Is It Worth Investing in Beam Therapeutics Inc (NASDAQ: BEAM) Right Now?
Company’s 36-month beta value is 2.35.Analysts have differing opinions on the stock, with 10 analysts rating it as a “buy,” 4 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for BEAM is 85.97M, and currently, short sellers hold a 21.90% ratio of that floaft. The average trading volume of BEAM on April 30, 2025 was 2.20M shares.
BEAM’s Market Performance
The stock of Beam Therapeutics Inc (BEAM) has seen a -2.92% decrease in the past week, with a -1.23% drop in the past month, and a -25.55% fall in the past quarter. The volatility ratio for the week is 4.13%, and the volatility levels for the past 30 days are at 10.05% for BEAM. The simple moving average for the last 20 days is 10.18% for BEAM’s stock, with a simple moving average of -22.99% for the last 200 days.
Analysts’ Opinion of BEAM
Many brokerage firms have already submitted their reports for BEAM stocks, with BofA Securities repeating the rating for BEAM by listing it as a “Buy.” The predicted price for BEAM in the upcoming period, according to BofA Securities is $42 based on the research report published on March 28, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see BEAM reach a price target of $40. The rating they have provided for BEAM stocks is “Sector Outperform” according to the report published on March 10th, 2025.
BEAM Trading at -13.85% from the 50-Day Moving Average
After a stumble in the market that brought BEAM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.28% of loss for the given period.
Volatility was left at 10.05%, however, over the last 30 days, the volatility rate increased by 4.13%, as shares surge +8.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.73% lower at present.
During the last 5 trading sessions, BEAM fell by -3.47%, which changed the moving average for the period of 200-days by -28.65% in comparison to the 20-day moving average, which settled at $17.50. In addition, Beam Therapeutics Inc saw -22.22% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BEAM starting from Bellon Christine, who sale 5,674 shares at the price of $18.35 back on Apr 01 ’25. After this action, Bellon Christine now owns 117,294 shares of Beam Therapeutics Inc, valued at $104,122 using the latest closing price.
Evans John M., the CEO of Beam Therapeutics Inc, sale 30,663 shares at $18.35 during a trade that took place back on Apr 01 ’25, which means that Evans John M. is holding 986,249 shares at $562,684 based on the most recent closing price.
Stock Fundamentals for BEAM
Current profitability levels for the company are sitting at:
- -6.54 for the present operating margin
- 0.74 for the gross margin
The net margin for Beam Therapeutics Inc stands at -5.93. The total capital return value is set at -0.45. Equity return is now at value -43.94, with -29.39 for asset returns.
Based on Beam Therapeutics Inc (BEAM), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -2.15. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -29.29.
Currently, EBITDA for the company is -415.57 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 28.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.82.
Conclusion
In a nutshell, Beam Therapeutics Inc (BEAM) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
